BCHT(SH:688276) 智通财经网·2025-10-09 07:49Core Viewpoint - The approval of the acellular combined vaccine for whooping cough, diphtheria, tetanus, and Haemophilus influenzae type b by the National Medical Products Administration represents a significant advancement for the company in its vaccine development pipeline [1] Group 1: Vaccine Approval - The company has received a clinical trial approval notice for the acellular combined vaccine from the National Medical Products Administration [1] - The vaccine is designed to prevent whooping cough, diphtheria, tetanus, and invasive infections caused by Haemophilus influenzae type b in infants aged 2 months and older [1] Group 2: Business Implications - Successful completion of clinical trials and subsequent market approval of the combined vaccine will enhance the company's vaccine development pipeline [1] - This development is expected to optimize the company's product structure and support comprehensive growth in its main business [1] - The introduction of this vaccine will provide the public with higher quality vaccination options and create new growth points for the company's performance [1]